Role of VIP1/PACAP receptors in postoperative ileus in rats
Abstract
- 1
Vasoactive intestinal polypeptide (VIP) is an inhibitory neurotransmitter in the enteric nervous system. We investigated the role of VIP1/PACAP receptors in postoperative ileus in rats.
- 2
Different degrees of inhibition of the gastrointestinal transit, measured by the migration of Evans blue, were achieved by skin incision, laparotomy or laparotomy plus mechanical stimulation of the gut.
- 3
The transit after skin incision or laparotomy was not altered by the VIP1/PACAP receptor antagonist Ac-Hisl,D-Phe2, K15, R16, VIP(3–7), GRF(8–27)-NH2 nor by the VIP1/PACAP receptor agonist K15, R16, VIP(1–7), GRF(8–27)-NH2 and the VIP2/PACAP receptor agonist RO 25-1553 (5 μg kg−1).
- 4
However, the transit after laparotomy plus mechanical stimulation was significantly enhanced by the VIP1/PACAP receptor antagonist, whereas it was further inhibited by the VIP1/PACAP receptor agonist. The combination of the VIP1/PACAP receptor agonist and antagonist counteracted the effect of both drugs alone. The VIP2/PACAP receptor agonist did not alter the effect of the VIP1/PACAP receptor antagonist.
- 5
The combination of the VIP1/PACAP receptor antagonist plus the nitric oxide (NO) synthase inhibitor l-nitroarginine had no effect on the transit after laparotomy plus mechanical stimulation, while the transit after skin incision was significantly decreased.
- 6
These findings suggest the involvement of VIP1/PACAP receptors, next to NO, in the pathogenesis of postoperative ileus. However, the combination of the VIP1/PACAP antagonist and the NO synthase inhibitor abolished the beneficial effect of each drug alone, suggesting the need for one of the inhibitory neurotransmitters to enable normal gastrointestinal transit.
British Journal of Pharmacology (1998) 124, 1181–1186; doi:10.1038/sj.bjp.0701954
Introduction
It is generally accepted that postoperative ileus involves the activation of an inhibitory reflex pathway with the efferent limb consisting of adrenergic fibres and the afferent limb consisting of capsaicin sensitive fibres (Dubois et al., 1973; Furness & Costa, 1974; Holzer et al., 1986; Livingston & Passaro, 1990). However, other mechanisms such as the activation of non-adrenergic non-cholinergic (NANC) nerves may contribute as well (Abrahamsson et al., 1979). We previously showed that mechanical stimulation of the small intestine and caecum triggers an additional non-adrenergic pathway mediated by nitric oxide (NO). Blockade of NO synthase by the arginine analogue L-nitroarginine completely reversed the additional inhibition of the transit induced by mechanical stimulation of the gut (De Winter et al., 1997). On the other hand, several authors suggest an involvement of vasoactive intestinal polypeptide (VIP) in the pathophysiology of small bowel obstruction and postoperative ileus (Basson et al., 1989; Espat et al., 1995). Espat et al. (1995) reported an improvement in postoperative small bowel transit in the rat after treatment with a non-selective VIP receptor antagonist, (D-p-Cl-Phe6, Leu17) VIP.
VIP and NO are both postulated as inhibitory neurotransmitters of the enteric nervous system (Goyal et al., 1980; Grider & Rivier, 1990; Boeckxstaens et al., 1991; Furness et al., 1992; Goyal & Hirano, 1996). Co-localisation of VIP and NO was demonstrated in the enteric neurons of the guinea pig, opossum and rat gastrointestinal tract (Costa et al., 1992; Ekblad et al., 1994; Lynn et al., 1995). The VIP receptors are a subclass of PACAP (pituitary adenylate cyclase activating peptide) type II receptors. The PACAP type I receptors have greater affinity for PACAP than for VIP, while the PACAP type II receptors are equally activated by PACAP and VIP (Usdin et al., 1994; Shuttleworth & Keef, 1995). Recently the VIP1/PACAP (VIP1) and VIP2/PACAP (VIP2) receptors were cloned with different distributions in the rat. The VIP2 receptor mRNA was most abundant in the stomach, whereas the VIP1 receptor mRNA was mostly present in the small intestine (Usdin et al., 1994). Subsequently, VIP1 and VIP2 receptor agonists and antagonists were developed. Ac-Hisl, D-Phe2, K15, R16, VIP(3-7), GRF(8-27)-NH2, a high affinity selective antagonist of the VIP1 receptor was synthesised and shown to be selective for the rat VIP1 receptor in vitro (Gourlet et al., 1997a). This VIP1 receptor antagonist was synthesised by analogy with the selective VIP1 receptor agonist derived from growth hormone releasing factor (GRF): K15, R16, VIP(l-7), GRF(8-27)-NH2 (Gourlet et al., 1997b). RO 25–1553 was proven to be a highly selective VIP2 receptor agonist in vitro (Gourlet et al., 1997c). Actually, there is no high affinity VIP2 receptor antagonist available. Therefore, in the present study we investigated the effect of the selective VIP1 receptor agonist and antagonist and the VIP2 receptor agonist in our rat model of postoperative ileus. As we previously demonstrated the involvement of NO in the pathogenesis of postoperative ileus we also investigated the interaction between NO and VIP.
Methods
Operation protocol
All procedures received approval from the Medical Ethical Committee of the University of Antwerp (U.I.A.). Male Wistar rats (150 – 240 g) were fasted for 48 h with free access to water. The operation protocol was previously described in detail (De Winter et al., 1997). Briefly, the rats were divided in three groups in a randomised way and underwent an abdominal operation under ether anaesthesia. Ether anaesthesia was chosen as, in contrast to pentobarbital, its effects on gastrointestinal motility were shown to last for only 1 h after the induction of the anaesthesia (Bueno et al., 1978; De Winter et al., 1997). The first group underwent an abdominal skin incision (SI) after shaving and disinfecting the abdomen. The second group underwent a laparotomy (LAP) consisting of the incision of the abdominal skin, the abdominal muscle layers and the peritoneum. The third group underwent a laparotomy followed by the evisceration and mechanical stimulation of the small intestine and caecum (L + M). Therefore, the small intestine and caecum were gently pulled out of the abdominal cavity and unfurled like a fan on two sterile gauzes covering the abdomen of the rat. Five minutes later the intestines were replaced in the abdominal cavity and the surgical wound was sutured. After the operation the rats were allowed to recover for 1 h. Then they received an intragastric injection of 0.1 ml Evans blue (50 mg in 1 ml 0.9% sodium chloride) (Tanila et al., 1993) via a specially designed orogastric cannula introduced through the mouth. Twenty minutes later the rats were killed by a cardiotomy under ether anaesthesia and the intestinal transit was measured from the pylorus to the most distal point of migration of Evans blue and expressed in cm migration.
Experimental protocol
In a first series of experiments we investigated the effect of different doses of the VIP1 receptor antagonist on the transit after the laparotomy plus mechanical stimulation. Therefore the rats were randomly divided in four groups before they underwent a laparotomy plus mechanical stimulation. The first group received an intravenous (i.v.) injection of 0.9% sodium chloride and served as control group. The second group was injected i.v. with the VIP1 receptor antagonist Ac-Hisl,D-Phe2, K15, R16, VIP(3–7), GRF(8-27)-NH2 in a dose of 3 μg kg−1 (Gourlet et al., 1997a). This concentration was similar to the concentration of the non-selective VIP receptor antagonist used by Espat et al. (1995). The third group received an i.v. injection of 5 μg kg−1 VIP1 receptor antagonist and the fourth group received a dose of 10 μg kg−1 VIP1 receptor antagonist 1 min before the laparotomy plus mechanical stimulation.
In a second series of experiments the effect of the VIP1 receptor agonist and the VIP1 receptor antagonist was tested on the intestinal transit after the three different operations. The rats were randomly divided in four groups. The first group served as control group and received an i.v. injection of 0.9% sodium chloride in the tail vein. Then the rats underwent a skin incision, laparotomy or laparotomy plus mechanical stimulation. The second group received an i.v. injection of the VIP1 receptor antagonist Ac-Hisl,D-Phe2, K15, R16, VIP(3-7), GRF(8–27)-NH2 (5 μg kg−1) 1 min before the operation. The third group received an i.v. injection of the VIP1 receptor agonist K15, R16, VIP(1–7), GRF(8–27)-NH2 (5 μg kg−1) 1 min before the operation (Gourlet et al., 1997b). The fourth group was injected i.v. with the VIP1 receptor antagonist immediately followed by an i.v. injection of the VIP1 receptor agonist 1 min before the operation.
In a third series of experiments we tested possible interaction of the VIP1 receptor antagonist with the VIP2 receptor. The rats were divided randomly in four groups. The first group served as control group and received an i.v. injection of 0.9% sodium chloride in the tail vein. Then they underwent a skin incision, laparotomy or laparotomy plus mechanical stimulation. The second group received an i.v. injection of the VIP1 receptor antagonist (5 μg kg−1) 1 min before the operation. The third group received an i.v. injection of RO 25–1553 (5 μg kg−1), a selective VIP2 receptor agonist (Gourlet et al., 1997c), 1 min before the operation. This dose was chosen in analogy with the dose of the VIP1 receptor agonist. The fourth group received an i.v. injection of the VIP1 receptor antagonist immediately followed by an i.v. injection of the VIP2 receptor agonist.
In a fourth series of experiments we investigated the interaction between NO and VIP on the transit after the laparotomy plus mechanical stimulation. Therefore the rats were randomly divided in four groups. The first group served as control group and received an i.v. injection of 0.9% sodium chloride 1 min before the laparotomy plus mechanical stimulation. The second group received an i.v. injection of the VIP1 receptor antagonist (5 μg kg−1) 1 min before the laparotomy plus mechanical stimulation. The third group received an i.v. injection of L-nitroarginine (5 mg kg−1), the NO synthase inhibitor, 1 min before the laparotomy plus mechanical stimulation. The fourth group received an i.v. injection of the VIP1 receptor antagonist (5 μg kg−1) immediately followed by an i.v. injection of L-nitroarginine (5 mg kg−1) 1 min before the laparotomy plus mechanical stimulation.
Finally, we investigated the effect of the combination of the VIP1 receptor antagonist and L-nitroarginine on the transit after skin incision. We previously demonstrated that the transit after skin incision was comparable to the transit in untreated rats (De Winter et al., 1997). Therefore, we investigated the effect of the combination therapy on the transit after skin incision. The rats were divided in two groups. The first group served as control group and received an i.v. injection of 0.9% sodium chloride 1 min before the skin incision. The second group received an i.v. injection of the VIP1 receptor antagonist (5 μg kg−1) immediately followed by an i.v. injection of L-nitroarginine (5 mg kg-1) 1 min before the skin incision.
Drugs used
The following drugs were used: diethyl ether (Merck, Darmstadt, Germany), Evans blue, Nω-nitro-L-arginine (Sigma, St. Louis, U.S.A.), sodium chloride 0.9% (Plurule®, Baxter, Lessines, Belgium). Ac-Hisl,D-Phe2, K15, R16, VIP(3–7), GRF(8–27)-NH2, the VIP1 receptor antagonist; K15, R16, VIP(1–7), GRF(8–27)-NH2, the VIP1 receptor agonist and RO 25–1553, the VIP2 receptor agonist were synthesised by the Department of Biochemistry and Nutrition, Medical School, Université Libre de Bruxelles, Brussels, Belgium. All products were dissolved in 0.9% sodium chloride.
Presentation of results and statistical analysis
The total length of the small intestine was not statistically different between the groups (data not shown). Therefore, results are expressed as cm migration of Evans blue and the measurements were made from the pylorus to the most distal point of migration of Evans blue. Group differences were assessed by simple factorial analysis of variance (ANOVA) and two-way analysis of variance. When the two way analysis of variance showed a signficant interaction between the factors, a one way analysis of variance followed by a Student-Newman-Keuls test for multiple comparisons was performed. A one way analysis of variance followed by a Dunnett test was used to study the dose-dependent effect of the VIP1 receptor antagonist. When only two groups were involved an unpaired Student's t-test was used. Values are shown as mean±s.e.mean for n indicating the number of rats used. P values ≤ 0.05 were considered to be significant. All data were analysed with the SPSS for Windows software (SPSS Inc., Chicago, IL, U.S.A.).
Results
Effect of different doses of the VIP1 receptor antagonist
To investigate the optimal dose of the VIP1 receptor antagonist, we treated the rats with different doses of the VIP1 receptor antagonist. The transit after the laparotomy plus mechanical stimulation in control rats was 17.4±1.7 cm (n = 6; Figure 1) and was not significantly altered by a dose of 3 μg kg−1 VIP1 receptor antagonist (20.4±1.6 cm; n = 6; Figure 1). However, the transit was significantly increased from 17.4±1.7cm in control rats to 25.1±2.0 cm in rats treated with a dose of 5 μg kg−1 and to 24.8±2.6 cm in rats treated with a dose of 10 μg kg−1 of the VIP1 receptor antagonist (n = 6; Figure 1). As the VIP1 receptor antagonist reached a maximal increase in the transit after a dose of 5 μg kg-1, we treated the rats with a dose of 5 μg kg−1 in all further experiments.
Effect of VIP1 receptor agonist and antagonist on intestinal transit
In control rats, treated with 0.9% sodium chloride, the transit after skin incision was 55.5±3.2 cm (n = 9; Figure 2). We previously showed that the transit after skin incision was comparable to the transit in untreated rats (De Winter et al., 1997). The laparotomy significantly delayed the transit to 43.1±2.6 cm (n = 9; Figure 2). This inhibition was even more pronounced when the laparotomy was followed by a mechanical stimulation of the gut: the transit was 17.8±1.8 cm (n = 9; Figure 2).
Treatment of the rats with the VIP1 receptor antagonist (5 μg kg−1), the VIP1 receptor agonist (5 μg kg−1) or the combination of the VIP1 receptor antagonist and agonist had no effect on the transit after skin incision or laparotomy (n = 9; Figure 2). However, the VIP1 receptor antagonist significantly increased the transit after the laparotomy plus mechanical stimulation from 17.8±1.8 cm in control rats to 25.8±2.3 cm in rats treated with the VIP1 receptor antagonist (n = 9; Figure 2). On the contrary, the VIP1 receptor agonist caused a small, but significant decrease in the transit after laparotomy plus mechanical stimulation from 17.8±1.8 cm in control rats to 13.3±2.1 cm in rats treated with the VIP1 receptor agonist (n = 9; Figure 2). The effect of the VIP1 receptor antagonist and the effect of the VIP1 receptor agonist were abolished when both treatments were combined: the transit after the laparotomy plus mechanical stimulation was 17.7±2.5 cm (n = 9) and thus comparable to the transit after laparotomy plus mechanical stimulation in control rats (Figure 2).
However, even after administration of the VIP1 receptor antagonist, the transit after laparotomy plus mechanical stimulation was still significantly different from the transit after skin incision or laparotomy in all treatment groups indicating that the VIP1 receptor antagonist was not able to completely reverse the additional inhibition induced by mechanical stimulation of the gut.
Effect of the VIP2 receptor agonist on intestinal transit
The VIP1 receptor antagonist (5 μg kg−1), the VIP2 receptor agonist (5 μg kg-1) or the combination of the VIP1 receptor antagonist and the VIP2 receptor agonist had no effect on the transit after skin incision or laparotomy compared to control rats (n = 9; Figure 3). The VIP1 receptor antagonist significantly increased the transit after the laparotomy plus mechanical stimulation from 18.2±2.1 cm in control rats to 26.2±2.0 cm in rats treated with the VIP1 receptor antagonist (n = 9; Figure 3). In contrast to the VIP1 receptor agonist, the VIP2 receptor agonist had no effect on the transit after the laparotomy plus mechanical stimulation: the transit was 19.3±2.5 cm (n = 9; Figure 3). The VIP2 receptor agonist was also not able to counteract the effect of the VIP1 receptor antagonist on the transit after laparotomy plus mechanical stimulation: the transit after combined treatment was 26.6±3.0 cm (n = 9) which was comparable to the transit after the VIP1 antagonist alone (Figure 3).
The transit after the laparotomy plus mechanical stimulation was significantly different from the transit after skin incision or laparotomy in all treatment groups.
Interaction between VIP and NO
We investigated the effect of combined treatment with the VIP1 receptor antagonist and L-nitroarginine on the transit after the laparotomy plus mechanical stimulation. The transit after the laparotomy plus mechanical stimulation in control rats was 16.6±1.8 cm, which was significantly increased to 25.4±1.7 cm after treatment with the VIP1 receptor antagonist (n = 7; Figure 4). Treatment of rats with the NO synthase inhibitor L-nitroarginine increased the transit after laparotomy plus mechanical stimulation to 32.7±3.7 cm (n = 7; Figure 4), which was significantly different from the transit after treatment with the VIP1 receptor antagonist. However, the combination of the VIP1 receptor antagonist and L-nitroarginine resulted in a transit of 18.4±1.5 cm which was comparable to the transit in control rats (n = 7; Figure 4).
Since both drugs, when administered together, lost their beneficial effect on the transit after the laparotomy plus mechanical stimulation, we investigated the effect of combined treatment on the transit after skin incision. We previously demonstrated that L-nitroarginine did not alter the transit after skin incision (De Winter et al., 1997) and in the present study we showed that also the VIP1 receptor antagonist had no effect on the transit after skin incision. However, the combination of L-nitroarginine and the VIP1 receptor antagonist significantly decreased the transit after skin incision from 59.8±4.1 cm in control rats to 47.8±2.9 cm in rats treated with the combination (n = 6–7; Figure 4).
Discussion
The enteric nervous system has different inhibitory neurotransmitters of which NO and VIP are believed to play an important role in the non-adrenergic non-cholinergic (NANC) relaxation (Goyal et al., 1980; Grider & Rivier, 1990; Boeckxstaens et al., 1991; Furness et al., 1992). In the present study, we demonstrate that next to NO (De Winter et al., 1997) also VIP, acting on the VIP1 receptors, is involved in the pathogenesis of postoperative ileus. This is, to the best of our knowledge, the first report on the use of a selective VIP1 and VIP2 receptor agonist and a selective VIP1 receptor antagonist in vivo. In our rat model of postoperative ileus, we applied three different nociceptive stimuli - skin incision, laparotomy and laparotomy plus mechanical stimulation of the gut - resulting in different degrees of inhibition of the gastrointestinal transit. Skin incision did not affect the gastrointestinal transit, whereas the transit was significantly delayed by the laparotomy. Mechanical stimulation of the small intestine and caecum resulted in an additonal inhibition of the gastrointestinal transit. Similar results were previously obtained by Bueno et al. (1978).
Recently the VIP1 and VIP2 receptor were cloned and it was shown that both receptors had a different distribution in the rat suggesting the possibility of differential effects (Usdin et al., 1994; Shuttleworth & Keef, 1995). Using the selective VIP1 receptor antagonist Ac-Hisl,D-Phe2, K15, R16, VIP(3–7), GRF(8–27)-NH2 (Gourlet et al., 1997a), the selective VIP1 receptor agonist K15, R16, VIP(1–7), GRF(8–27)-NH2 (Gourlet et al., 1997b) and the selective VIP2 receptor agonist RO 25–1553 (Gourlet et al., 1997c), we demonstrated the involvement of VIP1 receptors in the pathogenesis of postoperative ileus in rats. However, the VIP1 receptor antagonist, the VIP1 receptor agonist and the VIP2 receptor agonist had no effect on the transit after skin incision. Also Bojö et al. (1994) showed that VIP antiserum had no influence on basal gastric motility in the rat. Nevertheless, our findings support a role for the VIP1 receptor in the regulation of the intestinal transit after mechanical stimulation of the gut since the VIP1 receptor agonist significantly enhanced the inhibition of the transit induced by mechanical stimulation of the gut, whereas the VIP1 receptor antagonist significantly improved the transit after the laparotomy plus mechanical stimulation. The effect of the VIP1 receptor agonist and antagonist on the transit after the laparotomy plus mechanical stimulation disappeared when both treatments were combined. The VIP2 receptor agonist had no effect on the transit after the laparotomy plus mechanical stimulation and was also not able to alter the effect of the VIP1 receptor antagonist on the transit after the laparotomy plus mechanical stimulation, confirming the selectivity of the tested compounds. Previously, Espat et al. (1995) reported a beneficial effect of a non-selective VIP receptor antagonist on postoperative small bowel transit and a faster return of the migrating motor complex. In dogs with small bowel obstruction an increased VIP release was demonstrated in the portal and systemic circulation (Basson et al., 1989). Together, these results suggest an increased release of VIP, acting on the VIP1 receptors, after mechanical stimulation of the gut resulting in an inhibition of the gastrointestinal transit.
However, the VIP1 receptor antagonist was not able to completely reverse the additional inhibition of the transit induced by mechanical stimulation of the gut. This may result from incomplete blockade of VIP receptors or from the involvement of other inhibitory neurotransmitters. Previously, we showed that the NO synthase inhibitor, L-nitroarginine, completely reversed the additional inhibition induced by mechanical stimulation of the gut (De Winter et al., 1997). This effect of L-nitroarginine on the transit after laparotomy plus mechanical stimulation was more pronounced than the effect of the VIP1 receptor antagonist. NO and VIP are both important inhibitory neurotransmitters of the enteric nervous system (Goyal et al., 1980; Grider & Rivier, 1990; Boeckxstaens et al., 1991; Furness et al., 1992; Goyal & Hirano, 1996). As there are several hypotheses about the interaction between VIP and NO, depending on the species and the region under study (for review see Daniel et al., 1994), we investigated the interaction between NO and VIP in the pathogenesis of postoperative ileus. Surprisingly, the beneficial effects of the VIP1 receptor antagonist and L-nitroarginine disappeared when both were administered simultaneously. Since both NO and VIP mediate the descending inhibition of the peristaltic reflex (Furness et al., 1992; Grider, 1993; Goyal & Hirano, 1996), it is possible that blockade of both these inhibitory neurotransmitters results in decreased intestinal propulsion. However, blockade of one inhibitory neurotransmitter may have a beneficial effect on the transit after the laparotomy plus mechanical stimulation since the other inhibitory neurotransmitter sustains the descending inhibition of the peristaltic reflex. As such, blockade of both inhibitory neurotransmitters may overcome the observed beneficial effect of both blockers administered alone and prevent appropriate intestinal propulsion. Alternatively, there may be a chemical interaction in vivo between the VIP1 receptor antagonist and L-nitroarginine or a pharmacological synergism between NO and VIP.
To support our hypothesis we investigated the effect of blockade of the inhibitory neurotransmitters NO and VIP on the transit after skin incision. The transit after skin incision was not affected by NO blockade, as demonstrated previously (De Winter et al., 1997), nor by the VIP1 receptor antagonist as shown in the present study. However, blockade of both NO and VIP resulted in a decreased transit after skin incision indicating that at least one of these inhibitory neurotransmitters is needed to enable normal gastrointestinal transit. As we previously demonstrated that the transit after skin incision is comparable to the transit in normal conditions (De Winter et al., 1997), these results suggest that blockade of both inhibitory neurotransmitters inhibits normal intestinal transit.
In summary, previously we demonstrated the involvement of NO in the additional inhibition induced by mechanical stimulation of the gut. In this study we showed that next to NO also VIP, acting on the VIP1 receptor, contributes to the inhibition of the transit induced by mechanical stimulation of the gut, suggesting the involvement of NO and VIP in the pathogenesis of postoperative ileus. However, the combination of the VIP1 receptor antagonist and the NO synthase inhibitor abolished the beneficial effect of each inhibitor alone which suggests the need for one of the inhibitory neurotransmitters to enable normal gastrointestinal transit.
Acknowledgments
Benedicte De Winter is a research assistant of the Fund for Scientific Research-Flanders (F.W.O.), Belgium. This work was supported by the F.W.O.-Flanders, Belgium (Grant nr. G.0220.96) and by the Interuniversity Poles of Attraction Progam - Belgian State, Prime Minister's Office - Federal Office for Scientific, Technical and Cultural affairs. The authors wish to thank Mrs L. Van de Noort for typing the manuscript.